reports
Collegium to Participate in Upcoming Investor Conferences
Collegium to Participate in Upcoming Investor Conferences STOUGHTON, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: COLL) today announced that its management will participate in the following investor conferences: 25th Annual Needham Virtual Healthcare ConferenceFireside Chat Date and Time: Wednesday, April 15, 2026, at 2:15 p.m. ETVirtual A live webcast of the fireside chat will be available via the Investors section of the Company's website: . A replay of the webcast will be archived on the Company's website for 90 days following the presentation. Piper Sandler Spring Biopharma ...
Collegium Pharmaceutical Inc: 1 director
A director at Collegium Pharmaceutical Inc sold 13,976 shares at 34.924USD and the significance rating of the trade was 60/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ...
Collegium to Present New Real-World Data at PainConnect 2026
Collegium to Present New Real-World Data at PainConnect 2026 STOUGHTON, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: COLL) today announced it will present two posters featuring real-world data from its portfolio of differentiated pain medications at PainConnect 2026, the American Academy of Pain Medicine (AAPM)’s Annual Meeting, taking place in Salt Lake City, Utah from March 5-8, 2026. The presentations highlight real-world clinical insights from Collegium’s pain portfolio and reflect the Company’s continued focus on generating evidence that helps inform everyday practice. “U...
Paris Hilton Shares Her Experience with JORNAY PM and Launches New 'Em...
Paris Hilton Shares Her Experience with JORNAY PM and Launches New 'Embrace Your Sparkle' Campaign with Collegium to Empower the ADHD Community – Paris Hilton shares her personal ADHD journey and encourages others to see ADHD in a new light – –Together, Paris and Collegium are reframing common stereotypes and highlighting experiences that are often part of living with ADHD, including the importance of talking to a doctor and finding an individualized treatment plan – Credit: Ashley Osborn STOUGHTON, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasd...
Collegium to Participate in Upcoming Investor Conferences
Collegium to Participate in Upcoming Investor Conferences STOUGHTON, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: COLL) today announced that its management will participate in the following investor conferences: Leerink Partners Global Healthcare ConferenceMonday, March 9, 2026Miami, FL Jefferies Biotech on the Beach SummitTuesday, March 10, 2026Miami, FL The Citizens Life Sciences ConferenceTuesday, March 10, 2026Miami, FL Barclays 28th Annual Global Healthcare ConferenceFireside Chat Date and Time: Wednesday, March 11, 2026 at 9:00 a.m. ETMiami, FL A live webcast of the fire...
Collegium Reports Fourth Quarter and Full-Year 2025 Financial Results
Collegium Reports Fourth Quarter and Full-Year 2025 Financial Results – Generated Quarterly Net Revenues of $205.4 Million, Up 13% Year-over-Year, and Record Full-Year Net Revenues of $780.6 Million, Up 24% Year-over-Year – – Generated Record Quarterly and Full-Year Jornay PM® Net Revenue of $45.9 Million and $148.9 Million, Up 57% and 48%, Respectively, Year-over-Year – – Generated Quarterly Pain Portfolio Net Revenues of $159.6 Million, Up 5% Year-over-Year, and Record Full-Year Pain Portfolio Net Revenues $631.7 Million, Up 6% Year-over-Year – – Ended 2025 with Cash, Cash Equivalents...
Boston Legacy FC Announces Sensory Room Sponsorship with Collegium Pha...
Boston Legacy FC Announces Sensory Room Sponsorship with Collegium Pharmaceutical BOSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- today announced a multi-year partnership with , an emerging biopharmaceutical leader in the Boston area, naming the company an Official Partner of Boston Legacy FC. Through this collaboration, Boston Legacy FC and Collegium are working together to ensure that the club’s home games are welcoming and sensory-inclusive for all fans. As part of the partnership, the Collegium Sensory Room will be available at Gillette Stadium and Centreville Bank Stadium in 2026, and Wh...
Collegium to Report Fourth Quarter and Full-Year 2025 Financial Result...
Collegium to Report Fourth Quarter and Full-Year 2025 Financial Results on February 26, 2026 STOUGHTON, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: COLL) today announced that it will report fourth quarter and full-year 2025 financial results before the market opens on Thursday, February 26, 2026. Following the release of the financials, the Company will host a live conference call and webcast at 8:00 a.m. ET. Conference Call Information To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the “Collegium Pharmaceutical Q4 ...
Collegium to Present Four Real-World Data Posters at APSARD 2026 Annua...
Collegium to Present Four Real-World Data Posters at APSARD 2026 Annual Conference STOUGHTON, Mass., Jan. 15, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: COLL) today announced it will have four poster presentations highlighting real-world data from its ADHD product, Jornay PM (methylphenidate HCl), a central nervous system (CNS) stimulant indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in people 6 years of age and older and developed using a novel delayed-release extended-release delivery platform, at the American Professional Society of ADHD and Related Disorders (A...
Collegium Provides 2026 Financial Guidance and Business Update
Collegium Provides 2026 Financial Guidance and Business Update – Product Revenues, Net Expected in the Range of $805 Million to $825 Million – – Jornay PM® Net Revenue Expected in the Range of $190 Million to $200 Million – – Adjusted EBITDA* Expected in the Range of $455 Million to $475 Million – STOUGHTON, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), today announced its 2026 full-year financial guidance and provided a business update. “2025 was a year of record growth for Collegium and we are excited to begin 2026 with significant momentum ...
Collegium Announces the Closing of $980 Million Syndicated Credit Faci...
Collegium Announces the Closing of $980 Million Syndicated Credit Facility Five-Year Financing with Favorable Terms that Significantly Reduce Interest Rate STOUGHTON, Mass., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), today announced the closing of its inaugural syndicated credit facility. The new aggregate $980 million credit facility will mature in 2030 and consists of a $580 million initial Term Loan, $300 million Delayed Draw Term Loan, and $100 million revolving credit facility (collectively the “Credit Facility”). The initial Term Loan was used...
Collegium to Participate in Upcoming Investor Conferences
Collegium to Participate in Upcoming Investor Conferences STOUGHTON, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: COLL) today announced that its management will participate in the following investor conferences: Jefferies London Healthcare ConferencePresentation Date and Time: Wednesday, November 19, 2025, at 8:00 a.m. GMTLondon, UK The presentation will be webcast live and can be accessed from the Investors section of the Company's website: . A replay of the webcast will be archived on the Company's website for 90 days following the presentation. Piper Sandler 37th Annual Health...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
ATNI ATN INTERNATIONAL INC.
PAHC PHIBRO ANIMAL HEALTH CORPORATION CLASS A
LGND LIGAND PHARMACEUTICALS INCORPORATED
PLNT PLANET FITNESS INC. CLASS A
HOO HERBALIFE NUTRITION LTD.
COLL COLLEGIUM PHARMACEUTICAL INC.
AMBA AMBARELLA INC.
SKY SKYLINE CHAMPION CORPORATION
NYT NEW YORK TIMES COMPANY CLASS A
DLX DELIGNIT AG
MTSI MACOM TECHNOLOGY SOLUTIONS HOLDINGS INC.
NOMDN NOMAD FOODS LTD.
LILA LIBERTY LATIN AMERICA A
DUBA DRDGOLD LTD. ADS
BW BABCOCK & WILCOX ENTERPRISES
SITM SITIME
LZ LEGALZOOM.COM INC
DERM JOURNEY MEDICAL CORP
COHR COHERENT CORP
GPCR STRUCTURE THERAPEUTICS
SBGI SINCLAIR INC
FBYD FALCONS BEYOND GLOBAL INC
MRX MAREX GROUP PLC
LB LANDBRIDGE COMPANY LLC
ORKA ORUKA THERAPEUTICS INC
ECG_w EVERUS CONSTRUCTION GROUP INC.
BKTI BK TECHNOLOGIES CORP
RAL RALLIANT CORP
Collegium Reports Third Quarter 2025 Financial Results; Raises 2025 Gu...
Collegium Reports Third Quarter 2025 Financial Results; Raises 2025 Guidance – Generated Record Quarterly Net Revenue of $209.4 Million, Up 31% Year-over-Year – – Generated Record Quarterly Jornay PM® Net Revenue of $41.8 Million; Grew Prescriptions by 20% Year-over-Year – – Generated Record Quarterly Pain Portfolio Net Revenue of $167.6 Million, Up 11% Year-over-Year, with All Three Core Products Growing Year-over-Year – – Raised Full-Year 2025 Net Revenue Guidance to be in the Range of $775 to $785 Million and Adjusted EBITDA Guidance in the Range of $460 to $470 Million – – Ended Q3...
Paris Hilton Collaborates with Collegium Pharmaceutical to Share Her P...
Paris Hilton Collaborates with Collegium Pharmaceutical to Share Her Personal ADHD Journey and Experience with Treatment – Long-time advocate, Paris Hilton, shares her personal ADHD journey from childhood to adulthood to encourage others to speak to their healthcare provider about appropriate treatment options – STOUGHTON, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified biopharmaceutical company, and Paris Hilton, entrepreneur, musician, author, and advocate, are collaborating to share her personal experience living ...
Collegium to Report Third Quarter 2025 Financial Results on November 6...
Collegium to Report Third Quarter 2025 Financial Results on November 6, 2025 STOUGHTON, Mass., Oct. 23, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: COLL) today announced that it will report third quarter 2025 financial results before the market opens on Thursday, November 6, 2025. Following the release of the financials, the Company will host a live conference call and webcast at 8:00 a.m. ET. Conference Call Information To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the “Collegium Pharmaceutical Q3 2025 Earnings Call.” An audio we...
Collegium Announces Poster Presentations at the American Academy of Ch...
Collegium Announces Poster Presentations at the American Academy of Child & Adolescent Psychiatry and Neuroscience Education Institute Conferences STOUGHTON, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: COLL) today announced it will have poster presentations highlighting real-world data from its differentiated neuropsychiatry product, Jornay PM, (methylphenidate HCl), a central nervous system (CNS) stimulant for the treatment of attention deficit hyperactivity disorder (ADHD) in people 6 years of age and older at the American Academy of Child & Adolescent Psychiatry (AACAP) and Neur...
Collegium to Celebrate 10-Year Anniversary with Nasdaq Opening Bell Ri...
Collegium to Celebrate 10-Year Anniversary with Nasdaq Opening Bell Ringing – Collegium to Ring Nasdaq Opening Bell on October 14, 2025 – STOUGHTON, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: COLL) today announced that its management team will ring the Nasdaq opening bell on October 14, 2025 at 9:30 a.m. ET in celebration of its 10-year anniversary as a publicly traded company on the Nasdaq Stock Market. “Since its inception, Collegium has remained dedicated to improving the lives of patients with serious medical conditions. That commitment has fueled both our growth and the im...
Collegium to Participate in Upcoming Investor Conferences
Collegium to Participate in Upcoming Investor Conferences STOUGHTON, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: COLL) today announced that its management will participate in the following investor conferences: 2025 Wells Fargo Healthcare ConferenceThursday, September 4, 2025Boston, MA Morgan Stanley 23rd Annual Global Healthcare ConferenceFireside Chat Date and Time: Monday, September 8, 2025 at 2:35 p.m. ETNew York, NY A live webcast of the fireside chat will be available via the Investors section of the Company's website: . A replay of the webcast will be archived on the Comp...
Collegium to Present Nine Real-World Data Posters at PAINWeek 2025 Ann...
Collegium to Present Nine Real-World Data Posters at PAINWeek 2025 Annual Meeting STOUGHTON, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: COLL) today announced it will present nine posters showcasing real-world data from its differentiated pain portfolio at PAINWeek 2025, taking place in Las Vegas, NV, September 2-5, 2025. The posters will highlight real-world data from the company’s portfolio of pain treatments and reflect Collegium’s continued commitment to responsible pain management. “We are pleased to present this new research to the pain care community,” said Thomas Smith, M....
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.